EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

01 مايو 2024 11:03:28 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

30 أبريل 2024 17:26:55 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

22 أبريل 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

28 مارس 2024 08:15:03 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

25 مارس 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

06 مارس 2024 16:31:01 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

29 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

21 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

11 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

09 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

28 نوفمبر 2023 06:59:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

24 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

08 نوفمبر 2023 17:38:16 بحسب Nasdaq GlobeNewswire

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

30 أكتوبر 2023 16:45:13 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023

19 أكتوبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

02 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

30 أغسطس 2023 05:59:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

08 أغسطس 2023 16:31:58 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

08 أغسطس 2023 07:15:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

31 يوليو 2023 16:05:00 بحسب Nasdaq GlobeNewswire